Drug and Therapeutics Bulletin Podcast
In this podcast recorded in early March, James Cave (Editor-in-Chief) and David Phizackerley (Deputy Editor) talk about the April 2024 issue of DTB. They discuss the editorial that questions whether drug safety alerts are effective in changing practice and whether more needs to be done to implement safety recommendations (https://dtb.bmj.com/content/62/4/50). They review the Medicines and Healthcare products Regulatory Agency's latest risk minimisation measures for using valproate, which include a guide for healthcare professionals, a guide for patients, an annual risk acknowledgement form and an information card for patients (https://dtb.bmj.com/content/62/4/53). The main article considers the evidence for a new progestogen only pill containing drospirenone (https://dtb.bmj.com/content/62/4/55). They begin by discussing recent concerns over neuropsychiatric reactions associated with montelukast.
Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page (https://podcasts.apple.com/gb/podcast/dtb-podcast/id307773309). If you want to contact us please email [email protected]. Thank you for listening.
In this podcast recorded in BMA House in December, James Cave (Editor-in-Chief) and David Phizackerley (Deputy Editor) talk about the January 2024 issue of DTB. They discuss continuity of care in general practice and the benefits it offers (https://dtb.bmj.com/content/62/1/2). They discuss a safety alert issued by the Medicines and Healthcare products Regulatory Agency that highlights a very small number of reports of new-onset or aggravation of pre-existing myasthenia gravis associated with statins (https://dtb.bmj.com/content/62/1/4). The main article is an overview of the management of acne (https://dtb.bmj.com/content/62/1/6). They begin the podcast by providing a brief update on the results of a trial that assessed the effect of semaglutide on cardiovascular outcomes in people aged ≥45 years with cardiovascular disease (but not diabetes) and a BMI ≥27 kg/m2 (plot spoiler: make sure you know your ARRs from your RRRs).
Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page (https://podcasts.apple.com/gb/podcast/dtb-podcast/id307773309). If you want to contact us please email [email protected]. Thank you for listening.
In this podcast, James Cave (Editor-in-Chief) and David Phizackerley (Deputy Editor) talk about the September 2023 issue of DTB. They discuss concerns over redacted data in NICE appraisal documents (https://dtb.bmj.com/content/61/9/130). They review a placebo-controlled study that assessed the use of spironolactone for women with acne (https://dtb.bmj.com/content/61/9/132). The main article explores anticholinergic burden and the risk of cognitive decline, dementia and increased mortality associated with long-term use of drugs with anticholinergic activity (https://dtb.bmj.com/content/61/9/135).
Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page (https://podcasts.apple.com/gb/podcast/dtb-podcast/id307773309). If you want to contact us please email [email protected]. Thank you for listening.
In this podcast, James Cave (Editor-in-Chief) and David Phizackerley (Deputy Editor) talk about the August 2023 issue of DTB. They discuss measurement of fractional exhaled nitric oxide (FeNO) in the management of asthma (https://dtb.bmj.com/content/61/8/114). They review a study that assessed the use of H. pylori eradication in people taking low-dose aspirin (https://dtb.bmj.com/content/61/8/116). The main article explores the evidence for the use of finerenone for CKD associated with type 2 diabetes (https://dtb.bmj.com/content/61/8/120).
Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page (https://podcasts.apple.com/gb/podcast/dtb-podcast/id307773309). If you want to contact us please email [email protected]. Thank you for listening.
In this podcast, James Cave (Editor-in-Chief) and David Phizackerley (Deputy Editor) talk about the July 2023 issue of DTB. They discuss evidence-based medicine, access to evidence and increasing use of press releases and social media to present evidence (https://dtb.bmj.com/content/61/7/98). They talk about the safety of isotretinoin (https://dtb.bmj.com/content/61/7/99) and review a study that assessed the accuracy of conflict of interest statements in clinical guidelines (https://dtb.bmj.com/content/61/7/100). The main review article explores the evidence for cardiac and renal effects of SGLT2 inhibitors (https://dtb.bmj.com/content/61/7/103). They begin by discussing the impact of the shortage of Utrogestan.
Your feedback is valuable to us. Should you encounter any bugs, glitches, lack of functionality or other problems, please email us on [email protected] or join Moon.FM Telegram Group where you can talk directly to the dev team who are happy to answer any queries.